XTalks

NOVEMBER 30, 2023

More Investigational Therapies for HIV Are on the Way American Gene Technologies, a pioneering biotech company headquartered in Rockville, Maryland, has released promising results from its Phase I trial of AGT103-T, a gene therapy designed for individuals with chronic HIV disease. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

DECEMBER 12, 2022

According to the publication, “A small clinical trial has shown that researchers can use CRISPR gene editing to alter immune cells so that they will recognise mutated proteins specific to a person’s tumours. Those cells can then be safely set loose in the body to find and destroy their target. . “It References .

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

FEBRUARY 28, 2024

Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. In glioblastoma, as with many other highly recurrent cancers, tumour cells that escape treatment develop multiple genetic adaptations that allow them to proliferate.

Development 65

Development Research Drugs Antibody 65

Cloudbyz

MARCH 6, 2024

Personalized Medicine: Biologics offer the potential for personalized treatment approaches by taking into account individual variations in genetics, immune responses, and disease characteristics. Challenges and Future Directions: Despite their immense promise, biologics are not without challenges.

Gene 75

Gene Immune Response Manufacturing Gene Therapy 75

The Pharma Data

JANUARY 17, 2021

–( BUSINESS WIRE )– Genus plc (LSE: GNS), a global biotechnology leader in animal genetics, today reported continued strong performance across its operations for the six-months period ending December 31, 2020. 18, 2021 07:00 UTC. BASINGSTOKE, England & MADISON, Wis.–( and £49.0m

Containment 52

Containment Genetics Gene Editing Production 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Worldwide Clinical Trials

MAY 30, 2024

Biotech Solutions: The Emergence of Various Cell, Gene, & Immunotherapy Options in ALS One up-and-coming area of research is gene therapy, which broadly encompasses any therapeutics that add or edit genetic material.

Gene 204

Gene Clinical Trials Clinical Trials Gene Therapy 204

XTalks

DECEMBER 29, 2022

In 2022 alone, the US regulator approved four new gene therapies, showing the high interest in getting these therapies to market. In 2023, a number of gene therapies are expected to get the FDA green light. Given their precise targeting, gene therapies have largely been focused on oncology indications followed by rare genetic diseases.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

pharmaphorum

JANUARY 10, 2022

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

XTalks

JANUARY 4, 2024

Hemophilia B, also known as congenital Factor IX (FIX) deficiency or Christmas disease, is a rare genetic bleeding disorder caused by a deficiency or defect in the FIX clotting protein. Pfizer said that according to the World Federation of Hemophilia, more than 38,000 people worldwide were living with hemophilia B in 2021.

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

XTalks

DECEMBER 22, 2021

The RNA Revolution: From mRNA Vaccines to RNA Editing. The power of its real-world application was demonstrated by the resounding success of the mRNA COVID-19 vaccines. The mRNA COVID-19 vaccines have showcased the speed, versatility, scalability and flexibility that mRNA-based interventions offer.

Life Science 98

Life Science RNA Vaccination Vaccine 98

Drug Discovery World

APRIL 16, 2023

DDW’s Megan Thomas rounds up highlights from Sunday 16 April at AACR 2023, from promising trial results for a personalised mRNA-based cancer vaccine to winners of lifetime achievement awards. She is being recognised for her pioneering research dedicated to discovering and defining the role of NKX3.1

Clinical Trials 52

Clinical Trials Clinical Trials Research Vaccination 52

pharmaphorum

AUGUST 31, 2022

The information provided gives a general background on the development of gene therapies, how they function in the body and how they are delivered. It seems the FDA is trying to get ahead of any scepticism about gene therapies that proved complicated when encouraging uptake of COVID-19 vaccines. A broadening pipeline.

Gene Therapy 98

Gene Therapy Gene Gene Editing DNA 98

Pharma Marketing Network

JANUARY 20, 2021

In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic. Regarding OWS’s support for vaccine development, Dr Slaoui noted that 5 of the 6 vaccines selected (from a total of 94 programs) are currently in phase 3 development or approved.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

Drug Discovery World

MAY 30, 2023

Very recent data from Moderna’s and BioNTech’s personalised vaccines in combination with ICIs in melanoma and pancreatic cancer respectively have shown dramatic improvements when given as part of a triple combination (vaccine plus ICI and chemo/radiotherapy).

Research 52

Research Drugs Protein RNA 52

Drug Discovery World

JANUARY 26, 2023

Research into HIV blossomed throughout 2022, with ViiV Healthcare’s combination therapy for HIV-1 gaining approval in Japan; and research moving forward towards a one-time treatment for HIV as well as a vaccine. In terms of activity, a number of large-scale acquisitions took place, with Pfizer’s purchase of Biohaven for $11.6

Development 98

Development Drugs Clinical Trials Clinical Trials 98

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Drug Discovery World

FEBRUARY 22, 2024

Leukodystrophies are rare and almost exclusively genetic diseases characterised by a process of demyelination (damage to the myelin sheath) of the central and peripheral nervous system. The process is primitive in appearance and non-inflammatory and leads to cerebral sclerosis.

Drugs 59

Drugs Gene Clinical Trials Clinical Trials 59

Pharmaceutical Technology

MAY 26, 2023

Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines. As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate gene sequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA.

DNA 130

DNA Manufacturing Gene Therapy Gene 130

Pharmaceutical Technology

FEBRUARY 20, 2023

The capabilities of Viroclinics and DDL allowed us to rapidly test repurposed drugs, new vaccines and antiviral solutions for the prevention and treatment of patients affected by COVID-19 in 2020. The technology platforms are almost the same. The opportunity here for our expanded CRO to advance personalised medical solutions is huge.

Research 130

Research Clinical Trials Clinical Trials Trials 130